Quotables
"Without question, the greatest invention in the history of mankind is beer. Oh, I grant you that the wheel was also a fine invention, but the wheel does not go nearly as well with pizza."
Dave Barry
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7329749 | Piperazinylcarbonylquinolines and -isoquinolines Compound of the formula (I) in which R1, R2 and alk are as defined in Claim 1, are potent 5-HT2A antagonist and are suitable for the treatment of psychoses, schizophrenia, depression, neurological disorders, memory disorders, Parkins... | 02/12/2008 |
| 7319105 | Cytotoxic agents The invention provides compounds of the invention pharmaceutical compositions comprising a compound of the invention, processes for preparing compounds of the invention, intermediates useful for preparing compounds of the invention, and therapeutic methods for treat... | 01/15/2008 |
| 7307080 | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage The disclosure relates to compounds, pharmaceutical compositions and methods for inhibiting PARP by use of the disclosed compositions. The compounds of the disclosure have the following structures I, II and III: ... | 12/11/2007 |
| 7208492 | Topoisomerase-targeting agents The invention provides compounds of formula I or formula II: wherein: the bond represented by --- is a single bond or a double bond, and R1–R5, X, and Y have any of the meanin... | 04/24/2007 |
| 7153350 | Water soluble colorants for ink jet printing In accordance with one embodiment of the present invention, a colorant in an ink jet ink formulation is disclosed. The colorant comprises an organic dye chromophore with at least one functional group Y containing one or more primary, secondary or tertiary amino grou... | 12/26/2006 |
| 7151102 | Phthalazinone derivatives A method of treatment of a disease of the human or animal body mediated by PARP comprising administering to such a subject a therapeutically effective amount of a compound of formula: or an isomer, salt, solvate,... | 12/19/2006 |
| 7125989 | Hetero diels-alder adducts of pentacene as soluble precursors of pentacene The present invention describes organic solvent-soluble Diels-Alder adducts of polycyclic aromatic compounds, such as, oligothiophene, perylene, benzo[ghi]perylene, coronene and polyacenes, with variety of dienophiles containing at least one heteroatom and in some c... | 10/24/2006 |
| 7105661 | Process for manufacturing morpholino-nucleotides, and use thereof for the analysis of and labelling of nucleic acid sequences The invention relates to the use of morpholino-nucleosides of formula: in which R1 represents a nucleic base and R2 represents a group corresponding to one of the following formulae: | 09/12/2006 |
| 7081526 | Process for manufacturing morpholino-nucleotides, and use thereof for the analysis of and labelling of nucleic acid sequences The invention relates to the use of morpholino-nucleosides of formula: in which R1 represents a nucleic base and R2 represents a group corresponding to one of the following formulae: | 07/25/2006 |
| 7053093 | Bicyclic and tricyclic hetroaromatic compounds Disclosed are compounds of the formula: and the pharmaceutically acceptable salts thereof, wherein W, Q, X, X1, Y and Z are as defined herein. These compounds bind with high selectivity and/or high aff... | 05/30/2006 |
| 7049315 | Solubilized topoisomerase poisons The invention provides compounds of formula I: wherein A, B, W, Y, Z, and R1 have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also prov... | 05/23/2006 |
| 7011701 | Dye and ink jet printing ink A dye is disclosed, which is represented by the following formula: wherein Z is an atomic group necessary to form a 6-membered nitrogen containing aromatic ring; R11 is a hydrogen bonding group; R12 | 03/14/2006 |
| 6992089 | Nitro and amino substituted topoisomerase agents The invention provides compounds of formula I: wherein R1-R9, W, and X have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provide... | 01/31/2006 |
| 6989387 | Nitro and amino substituted topoisomerase agents The invention provides compounds of formula I: wherein R1–R9, W, and X have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also provid... | 01/24/2006 |
| 6987109 | Solubilized topoisomerase poison agents The invention provides compounds of formula I: wherein A, B, W, Y, Z, and R1 have any of the meanings defined in the specification and their pharmaceutically acceptable sal... | 01/17/2006 |
| 6964964 | Topoisomerase poison agents The invention provides compounds of formula I: wherein A, B, W, Y, Z, R1, R3 and R4 have any of the meanings defined in the specification and their ph... | 11/15/2005 |
| 6946472 | Polycyclic compounds exhibiting anti-tumor activities This invention is concerned with novel polycyclic compounds of formula [I], wherein ring A, ring B, R1, R2, R3, R4, R5, R6, X, Y, R1′, R | 09/20/2005 |
| 6918958 | Acid pigment dispersants and pigment preparations The invention relates to pigment dispersants of the formula (I), and to pigment preparations including at least one organic pigment and at least one pigment disperant of the formula (I): wherein Q1, R1 | 07/19/2005 |
| 6872743 | sPLA2 inhibitors A novel class of tetracyclic compounds represented by the formula I wherein R1, R2, R3, R4, R5, R6, R7, A, B, C, D, E, and n are as defined is disclosed together with the use of such compounds for inhibiting sPLA2 medi... | 03/29/2005 |
| 6844433 | Nucleic acid labeling compounds Nucleic acid labeling compounds containing heterocyclic derivatives are disclosed. The heterocyclic derivative containing compounds are synthesized by condensing a heterocyclic derivative with a cyclic group (e.g. a ribofuranose derivative). The labeling compounds a... | 01/18/2005 |
| 6838461 | N-(indolcarbonyl-)piperazine derivatives Compounds of the formula I in which R1, R2, R4 and R5 have the meanings indicated in claim 1, are potent 5-HT2A antagonists and are suitable for the treatme... | 01/04/2005 |
| 6838560 | Process for manufacturing morpholino-nucleotides, and use thereof for the analysis of and labelling of nucleic acid sequences The invention relates to the use of morpholino-nucleosides of formula: in which R1 represents a nucleic base and R2 represents a group corresponding to one of the following formulae: ... | 01/04/2005 |
| 6747151 | Azo compounds for type I phototherapy Novel azo compounds and their bioconjugates for phototherapy and/or photodiagnosis of tumors and other lesions. The azo derivatives of the present invention are designed to absorb at the low-energy ultraviolet, visible, or near-infrared (NIR) region of the electroma... | 06/08/2004 |
| 6747039 | Aza-benzothiopyranoindazoles with antitumor activity The present invention relates to a group of aza-anthrapyrazole compounds having antitumor activity, and processes for their preparation. Compositions containing the aza-anthrapyrazole compounds and methods of treating tumors and cancer in mammals with the compounds ... | 06/08/2004 |
| 6740650 | Heterocyclic cytotoxic agents The invention provides compounds of formula I: wherein R1-R8 and A-G have any of the meanings defined in the specification and their pharmaceutically acceptable salts. The invention also prov... | 05/25/2004 |
| 6716828 | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage This invention relates to compounds, pharmaceutical compositions, and methods for the treatment or prevention of neural or cardiovascular tissue damage related to cerebral ischemia and reperfusion injury in an animal by administering Poly(ADP-ribose) polymerase (“... | 04/06/2004 |
| 6710047 | Phthalazines with angiogenesis inhibiting activity The invention relates to compounds of formula I, wherein r is 0 to 2, n is 0 to 2; m is 0 to 4; R1 and R2 (i) are in each case a lower alkyl, or (ii) together form a bridge in subformula I* | 03/23/2004 |
| 6699979 | Oligonucleotides having chiral phosphorus linkages Sequence-specific oligonucleotides are provided having substantially pure chiral Sp phosphorothioate, chiral Rp phosphorothioate, chiral Sp alkylphosphonate, chiral Rp alkylphosphonate, chiral Sp phosphoamidate, chiral Rp phosphoamidate, chiral Sp phospho... | 03/02/2004 |
| 6680326 | Polycyclic compounds Novel polycyclic compounds of the formula [I], ##STR1## wherein R1, R2, R3, R4, R5, R6, R7, ring A, ring B, X, Y and Z are as defined herein and the pharmaceutically acceptable s... | 01/20/2004 |
| 6635642 | PARP inhibitors, pharmaceutical compositions comprising same, and methods of using same The present invention relates to PARP inhibitors, pharmaceutical compositions comprising the same, and methods of using the same to treat tissue damage resulting from cell damage or death due to necrosis or apoptosis, effect neuronal activities not mediat... | 10/21/2003 |
| 6605610 | Aryl fused azapolycyclic compounds Compounds of the formula ##STR1## and their pharmaceutically acceptable salts, wherein R1, R2, and R3 are as defined herein; intermediates for the synthesis of such compounds, pharmaceutical compositions containing such co... | 08/12/2003 |
| 6559306 | Dye compounds This invention relates to new fluorescent or non-fluorescent dye compounds having a terminal hydroxy, carboxylic acid/ester or amino group and a process for their preparation. The new fluorescent or non-fluorescent dye compounds are useful as colorants fo... | 05/06/2003 |
| 6552021 | Pharmaceutical compounds A compound which is a heteroaromatic[a]phenazine carboxamide derivative of formula (I) ##STR1## wherein X is a five- or six-membered heteroaromatic ring which contains one or two nitrogen atoms and which is unsubstituted or substituted by C1 ... | 04/22/2003 |
| 6491749 | Core-extended perylene bisimides The present inventions relates to nucleus-extended perylenebisimides of formula (I) ##STR1## intermediates in the preparation of compounds (I) and processes for the preparation of those intermediates and also processes for the preparation of compound... | 12/10/2002 |
| 6486167 | Heterocyclic cytotoxic agents The present invention provides compounds of formula I: ##STR1## wherein the R substituents and atoms X and Y are as defined in specification. The present invention also provides pharmaceutical compositions and methods of inhibiting cancer cell growth.... | 11/26/2002 |
| 6469021 | Non-peptide antagonists of GLP-1 receptor and methods of use Non-peptide compounds that act as antagonists of the intestinal hormone glucagons-like peptide 1 (GLP-1) have a 9H-b-carboline central motif. The compounds exhibit advantageous physical, chemical and biological properties and inhibit GLP-1 peptide binding... | 10/22/2002 |
| 6440968 | Use of maduraohtalazine derivatives as inhibitors of proinflammatory cytokines The maduraphthalazine derivatives of the formula (4) ##STR1## are able to inhibit the effect of the cytokines interleukin-2, interleukin-4 and interleukin-5 and are suitable for the production of pharmaceuticals.... | 08/27/2002 |
| 6429311 | Compositions containing N-amino- and N-hydroxy-quinazolinones and methods for preparing libraries thereof The present invention is directed to certain N-amino- and N-hydroxy-quinazolinone compounds and synthetic methods for synthesis thereof, which compounds may find use in combinatorial libraries. More specifically, the invention is directed to the synthesis... | 08/06/2002 |
| 6426346 | 6-membered aromatics as factor Xa inhibitors The present application describes 6-membered aromatics of formula I: ##STR1## or pharmaceutically acceptable salt forms thereof, wherein D may be CH2 NH2 or C(.dbd.NH)NH2, which are useful as inhibitors of factor Xa.... | 07/30/2002 |
| 6380193 | Fused tricyclic compounds, methods and compositions for inhibiting PARP activity A compound of formula I: ##STR1## or a pharmaceutically acceptable salt, hydrate, ester, solvate, prodrug, metabolite, stereoisomer, or mixtures thereof.... | 04/30/2002 |
